These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18615451)

  • 1. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents.
    Steensma DP
    Am J Hematol; 2008 Sep; 83(9):693-4. PubMed ID: 18615451
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E; Dimopoulos MA; Zervas K; Terpos E
    Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESAs not the culprit: more studies required.
    Ludwig H; Anderson K; Dammacco F; Hedenus M; Osterborg A; Durie B
    Am J Hematol; 2008 Nov; 83(11):880; author reply 880-1. PubMed ID: 18785638
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
    Dharmarajan TS; Widjaja D
    Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erythropoiesis-stimulating agents: favorable safety profile when used as indicated].
    Adam M
    Strahlenther Onkol; 2008 Sep; 184(9):490. PubMed ID: 19016030
    [No Abstract]   [Full Text] [Related]  

  • 9. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
    Hadland BK; Longmore GD
    J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 15. Anemia therapy in kidney disease. What research reveals about ESA medication safety.
    Johns Hopkins Med Lett Health After 50; 2010 Nov; 22(9):1-2, 7. PubMed ID: 21066834
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use.
    Schrijvers D; De Samblanx H; Roila F;
    Ann Oncol; 2010 May; 21 Suppl 5():v244-7. PubMed ID: 20555090
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 19. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
    Schiavetto I; Pedrazzoli P; Basilico V; Siena S
    Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.